Synapse - David Spriggs

Search Within

David R Spriggs

Results (325)

The Src inhibitor AZD0530 demonstrates enhanced antiproliferative and anti-invasive activity in MUC16(+) A2780 ovarian carcinoma cells

Meeting Abstract

dos Santos, L. A.; Diaz, J. P.; Ma, X.; Thapi, D.; Yan, X. J.; Rosales, N.; Spriggs, D. R.
Gynecologic Oncology (2008)

Fulltext@MSK | Save

The MUC16/CA125 gene inhibits apoptosis in SK-OV-3 ovarian carcinoma cells

Meeting Abstract

Diaz, J. P.; dos Santos, L. A.; Rosales, N.; Thapi, D.; Ma, X.; Yan, X. J.; Spriggs, D. R.
Gynecologic Oncology (2008)

Fulltext@MSK | Save

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer

Journal Article

Konner, J.; Schilder, R. J.; DeRosa, F. A.; Gerst, S. R.; Tew, W. P.; Sabbatini, P. J.; Hensley, M. L.; Spriggs, D. R.; Aghajanian, C. A.
Gynecologic Oncology (2008)

Fulltext@MSK | Save

A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies

Journal Article

Iasonos, A.; Wilton, A. S.; Riedel, E. R.; Seshan, V. E.; Spriggs, D. R.
Clinical Trials (2008)

Fulltext@MSK | Save

Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission

Journal Article

Diefenbach, C. S. M.; Gnjatic, S.; Sabbatini, P.; Aghajanian, C.; Hensley, M. L.; Spriggs, D. R.; Iasonos, A.; Lee, H.; Dupont, B.; Pezzulli, S.; more...
Clinical Cancer Research (2008)

Fulltext@MSK | Save

Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in third-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results

Meeting Abstract

Vergote, I.; Finkler, N.; del Campo, J.; Lohr, A.; Hunter, J.; Matei, D.; Spriggs, D.; Kavanagh, J.; Vermorken, J.; Brown, G. L.; more...
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study

Meeting Abstract

Tew, W. P.; Colombo, N.; Ray-Coquard, I.; Oza, A.; del Campo, J.; Scambia, G.; Spriggs, D.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer

Meeting Abstract

Konner, J. A.; Fallon, K.; Pezzuli, S.; Iasonos, A.; Sabbatini, P.; Hensley, M.; Chiang, A.; Tew, W.; Spriggs, D.; Aghajanian, C.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Phase I trial of PTK787/ZK222584 (PTK/ZK) in combination with carboplatin (C) and paclitaxel (T) in platinum-sensitive recurrent epithelial ovarian (EOC), fallopian tube (FT), or primary peritoneal (PPC) cancers

Meeting Abstract

Juretzka, M. M.; Aghajanian, C.; Hensley, M. L.; Tew, W. P.; Spriggs, D.; Konner, J.; Chiang, A. C.; Pezzulli, S.; Kim, M.; Sabbatini, P.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Phase I study of LY573636-sodium, an acylsulfonamide anti-cancer compound with a novel mechanism of action, administered as 2-hour IV infusion in patients with advanced solid tumors

Meeting Abstract

Ilaria, R. L. Jr; Simon, G. R.; Sovak, M.; Burton, M. K.; Cleverly, A. L.; Sykes, A. K.; De Alwis, D. P.; Wagner, M. M.; Spriggs, D. R.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save